- Origin: Missouri
- Grant awarded in: 2017
- BioGenerator • Cortex Innovation Community • Skandalaris Center • Square One • Startup Connection • The BALSA Group • Venture Cafe
What is VaxNewMo?
VaxNewMo is dedicated to developing more affordable pneumococcal conjugate vaccines that provide broader protection against more strains of bacteria that cause pneumococcal pneumonia. To do this, we utilize our patented bioconjugation technology, which bypasses the dependency on the synthetic chemistry techniques previously required to manufacture conjugate vaccines. In essence, we have engineered the lab safe bacterium, E. coli, to manufacture pneumococcal conjugate vaccines faster, more reliable, and less expensive than traditional pharmaceutical companies can.
Christian Harding is Co-Founder and Chief Executive Officer for VaxNewMo.